Exelixis
EXEL
#1786
Rank
โ‚น814.53 B
Marketcap
โ‚น2,852
Share price
-0.09%
Change (1 day)
56.78%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): โ‚น23.20

According to Exelixis's latest financial reports the company's current EPS (TTM) is โ‚น24.54. In 2022 the company made an earnings per share (EPS) of โ‚น49.37 a decrease over its 2021 EPS that were of โ‚น64.10.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)โ‚น23.20-53.01%
2022โ‚น49.37-22.97%
2021โ‚น64.10100%
2020โ‚น32.05-65.09%
2019โ‚น91.81-53.91%
2018โ‚น199.21333.96%
2017โ‚น45.91-260.61%
2016-โ‚น28.58-58.75%
2015-โ‚น69.29-42.45%
2014-โ‚น120.395.3%
2013-โ‚น114.3343.48%
2012-โ‚น79.69-264.29%
2011โ‚น48.50-165.88%
2010-โ‚น73.62-32.54%
2009-โ‚น109.13-17.65%
2008-โ‚น132.5275.86%
2007-โ‚น75.36-25.64%
2006-โ‚น101.348.33%
2005-โ‚น93.54-42.86%
2004-โ‚น163.7030.34%
2003-โ‚น125.59-5.23%
2002-โ‚น132.52-0.65%
2001-โ‚น133.39-51.88%
2000-โ‚น277.17

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
โ‚น303.21 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚น275.46 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚น157.78 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น343.86 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น1,226 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น1,220 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น161.10 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น866.15-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น72.76-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA